GGrantIndex
← Leaderboards

Vala Sciences, Inc.

San Diego, CA

Compare ↔
$30,174,273
Total funding
36
Grants

Funding over time

peak $4.1M · FY200625
$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$30,174,273 · 36

By mechanism

R44$13,258,770 · 7
R42$8,409,578 · 5
N43$3,019,372 · 7
N44$1,954,960 · 2
R43$1,945,633 · 8
R41$1,536,017 · 5

Investigators at Vala Sciences, Inc.

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

Largest grants

TAS::75 0849::TAS R&D-OTHER SCIENCES-B RES$1,730,100
N43 · FY2011 · CA
An assay suite featuring hiPSC-derived neurons and support cells, to test toxicants and industrial chemicals for developmental neurotoxic effects$1,217,093
R44 · FY2024 · ES
Neural Circuits, Kinetics and Energetics HTS of Human iPSC-Neurons, -Microglia, and -Astrocytes: AI-Enabled Platform for Target ID, and Drug Discovery and Toxicity (e.g., Cancer Chemo & HIV ARTs)$1,139,473
R44 · FY2024 · MH
Neural Circuits, Kinetics and Energetics HTS of Human iPSC-Neurons, -Microglia, and -Astrocytes: AI-Enabled Platform for Target ID, and Drug Discovery and Toxicity (e.g., Cancer Chemo & HIV ARTs)$1,092,964
R44 · FY2025 · MH
A High Throughput Assay for Neural Crest Cell Migration & Toxicity$1,074,832
N44 · FY2014 · DA
Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes$1,056,800
R42 · FY2023 · HL
The hCNS-HIV/ARV assay system, a platform utilizing human iPSC-neurons/-microglia/-astrocytes to test HIV/AIDS therapeutics for neurotoxicity related to HIV-associated cognitive disroder (HAND)$975,197
R44 · FY2021 · MH
The hCNS-HIV/ARV assay system, a platform utilizing human iPSC-neurons/-microglia/-astrocytes to test HIV/AIDS therapeutics for neurotoxicity related to HIV-associated cognitive disroder (HAND)$940,992
R44 · FY2022 · MH
Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes$920,237
R42 · FY2024 · HL
TAS::75 0872::TAS SBIR PHASE II: VALA SCIENCES, TOPIC #44, DEVELOPMENT OF CELL-B$880,128
N44 · FY2011 · HL
Stem cell toxicology assays for cardiac differentiation$761,593
R44 · FY2016 · ES
HT Image Assay of Lipid Droplet Formation in Human Adipocytes$757,726
R44 · FY2008 · DK
An assay suite featuring hiPSC-derived neurons and support cells, to test toxicants and industrial chemicals for developmental neurotoxic effects$755,735
R44 · FY2025 · ES
Assay of chemicals for Parkinson's toxicity in human iPSC-derived neurons$752,246
R44 · FY2018 · ES
HT Image Assay of Lipid Droplet Formation in Human Adipocytes$745,749
R44 · FY2009 · DK
Assay of chemicals for Parkinson's toxicity in human iPSC-derived neurons$742,257
R44 · FY2019 · ES
Stem cell toxicology assays for cardiac differentiation$738,406
R44 · FY2017 · ES
Automated quantification of lipid droplets in fatty liver tissue sections$733,790
R42 · FY2011 · DK
Automated quantification of lipid droplets in fatty liver tissue sections$720,643
R42 · FY2012 · DK
Optogenetic Multiparametric Assay for HT Cardiotoxicity Testing$710,494
R42 · FY2013 · HL